FIBROBIOLOGICS INC
FBLGNASDAQ🏆 #3810 by market capUS Equity
$133.93▼ $5.93 (−4.43%)
Simulated price1h—
24h▼ 4.4%
7d—
14d—
30d—
1y—
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
46
Weak
No chart data available for FBLG.
Trading Snapshot
- Day Range
- $132.82 – $135.97
- 52-Week Range
- $0.62 – $12.80
- Volume
- $1.94B
- Avg Volume
- $2.42B
- Shares Outstanding
- 6.1M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $694,152
- Last Q Revenue
- $190,871
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-5.74
- Dividend Yield
- —
Why Investors Own FBLG
- ✓High-growth profile — revenue up +59.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$694,152▲ +59.5% YoY
Gross Margin (TTM)
38.6%▲ +3.8% YoY
Operating Income (TTM)
$127,030▲ +59.5% YoY
Free Cash Flow (TTM)
$61,780▲ +59.5% YoY
About FIBROBIOLOGICS INC
A company profile for FIBROBIOLOGICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Price Target
ⓘAverage Target
$133.44
▼ −0.4% Downside
High Target$156.71
Low Target$106.48
Based on 40 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
FIBROBIOLOGICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift FBLG price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
FIBROBIOLOGICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.